GSA Capital Partners LLP Makes New $95,000 Investment in Adaptimmune Therapeutics plc (NASDAQ:ADAP)

GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 99,662 shares of the biotechnology company’s stock, valued at approximately $95,000.

A number of other institutional investors have also recently added to or reduced their stakes in ADAP. Fullcircle Wealth LLC bought a new position in Adaptimmune Therapeutics during the third quarter valued at about $33,000. Vontobel Holding Ltd. boosted its stake in Adaptimmune Therapeutics by 230.8% during the 3rd quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares during the period. Long Focus Capital Management LLC lifted its holdings in shares of Adaptimmune Therapeutics by 15.6% during the second quarter. Long Focus Capital Management LLC now owns 12,346,417 shares of the biotechnology company’s stock worth $12,037,000 after buying an additional 1,662,184 shares during the last quarter. Finally, Renaissance Technologies LLC grew its stake in shares of Adaptimmune Therapeutics by 28.3% in the second quarter. Renaissance Technologies LLC now owns 1,786,341 shares of the biotechnology company’s stock worth $1,742,000 after acquiring an additional 394,566 shares during the last quarter. 31.37% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

ADAP has been the subject of a number of research reports. HC Wainwright reduced their price target on shares of Adaptimmune Therapeutics from $4.00 to $3.50 and set a “buy” rating for the company in a report on Thursday, November 14th. Guggenheim decreased their target price on Adaptimmune Therapeutics from $4.00 to $3.00 and set a “buy” rating on the stock in a research report on Friday, November 15th. Finally, StockNews.com cut Adaptimmune Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $3.16.

Adaptimmune Therapeutics Stock Performance

Adaptimmune Therapeutics stock opened at $0.70 on Tuesday. The firm has a market capitalization of $178.37 million, a P/E ratio of -3.17 and a beta of 2.26. Adaptimmune Therapeutics plc has a 52-week low of $0.42 and a 52-week high of $2.05. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.85 and a quick ratio of 3.82. The stock has a fifty day moving average price of $0.83 and a two-hundred day moving average price of $1.01.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.